Sinovac’s Eupolio Vaccine Gains Market Authorization in China

News
Article

Sinovac Biotech’s Eupolio vaccine, a Sabin inactivated poliovirus vaccine (sIPV), has gained marketing authorization in China.

Sinovac Biotech’s Eupolio vaccine, which is a Sabin inactivated poliovirus vaccines (sIPV) developed by Intravacc and out licensed to Sinovac, has gained marketing authorization in China from the Chinese National Medical Products Administration (NMPA).

The approval, which was announced in a July 20, 2021 press release, is a positive result for the ongoing efforts to eradicate the globe of polio. Intravacc had originally developed the vaccine for the purpose of providing low- and middle-income countries with the opportunity to produce their own safe polio vaccine.

According to the company press release, many vaccination campaigns to eradicate polio were put on hold or delayed during the COVID-19 pandemic. So, the approval of the Eupolio vaccine in China will help to close the gap between the supply and demand of inactivated polio vaccines for infants.

“This is a great example project in which Intravacc’s innovation and knowledge have been the foundation of the development of an affordable vaccine that contributes to the reduction of infectious disease burden on a global level,” said Jan Groen, Intravacc’s CEO, in the press release. “We have recently launched a similar program for our Avacc 10 COVID-19 nasal spray vaccine, intending to make this vaccine available to the world.”

Source: Intravacc

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes